IFRX (InflaRx NV) PEG Ratio: 0.00 (As of Jul. 01, 2026)


IFRX InflaRx NV IFRX
31 GF Score
Price $2.24
! 5 Warning Signs
View Full Analysis

What is InflaRx NV PEG Ratio?

InflaRx NV IFRX -3.03% 31 PEG Ratio is 0.00 as of Jul. 01, 2026. GuruFocus rates IFRX with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 95 Biotechnology companies, InflaRx NV ranks worse than 1052630.53% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, InflaRx NV's PE Ratio without NRI is 0.00. InflaRx NV's 5-Year EBITDA growth rate is 11.40%. Therefore, InflaRx NV's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for InflaRx NV's PEG Ratio or its related term are showing as below:



IFRX's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.98
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


InflaRx NV  (NAS:IFRX) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


InflaRx NV PEG Ratio Related Terms


InflaRx NV PEG Ratio Historical Data

* Premium members only.

The historical data trend for InflaRx NV's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InflaRx NV PEG Ratio Chart

InflaRx NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

InflaRx NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IFRX vs BCYC, ELDN, ZNTL: PEG Ratio Comparison

For the Biotechnology subindustry, InflaRx NV's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's PEG Ratio distribution charts can be found below:

* The bar in red indicates where InflaRx NV's PEG Ratio falls into.


IFRX
31GF Score
InflaRx NV IFRX
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InflaRx NV PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

InflaRx NV's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/11.40
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 0.00 mean?
InflaRx NV (IFRX) has a PEG Ratio of 0.00 as of Jul. 01, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on InflaRx NV and its competitors. According to the industry distribution chart, InflaRx NV ranks #999999 out of 95 companies in the Biotechnology industry.
Is InflaRx NV's PEG Ratio too high?
InflaRx NV's current PEG Ratio is 0.00. Based on the distribution chart, InflaRx NV ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, InflaRx NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's PEG Ratio compare to BCYC and ELDN?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #999999 out of 95 companies for PEG Ratio. This places InflaRx NV in the lower half of its industry. The industry median PEG Ratio is 1.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.98, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on InflaRx NV and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InflaRx NV's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (IFRX) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. InflaRx NV's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For InflaRx NV (IFRX), the current PEG Ratio is 0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InflaRx NV Business Description

Other Exchanges IF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
31GF Score

Get the complete analysis for IFRX

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.24
Price